• Explore /
  • Poster
  • / Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.

Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.

Abstract Poster

Authors

null

Rachel Lubong Sabado

Icahn School of Medicine at Mount Sinai, New York, NY

Rachel Lubong Sabado , Anna C. Pavlick , Sacha Gnjatic , Crystal M Cruz , Isabelita Vengco , Farah Hasan , Farbod Darvishian , Luis Chiriboga , Rose Marie Holman , Juliet Escalon , Caroline Muren , Crystal Escano , Ethel Yepes , Dunbar Sharpe , Sylvia Adams , Patrick Alexander Ott , Achim A Jungbluth , Linda S. Pan , Ralph Rudolph Venhaus , Nina Bhardwaj

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT00821652

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 9086)

DOI

10.1200/jco.2014.32.15_suppl.9086

Abstract #

9086

Poster Bd #

290

Abstract Disclosures

Similar Posters

Poster

2016 ASCO Annual Meeting

Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.

Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.

First Author: Michael William Lattanzi

First Author: Rachel Lubong Sabado

First Author: Oliver Klein

First Author: Guillermo De Velasco